Bausch Health Companies Inc stock has seen some fluctuations recently, with both positive and negative movements over the past week.
This week, Bausch Health Companies Inc (BHC.TO) closed at C$8.79 after a modest increase of 0.46% on Monday. However, the stock has experienced a slight decline of 0.45% over the past week, despite an impressive gain of 33.84% over the last month. Investors are closely monitoring the company's recent announcements and market performance as they navigate through a challenging year.
Advertisement
Bausch Health Companies Inc
BHC.TO
BHC.TO
Bausch Health Companies Inc
WealthAwesomeMarket cap
$3.28B
52W high
$11.08
52W low
$6.10
1W change
-0.45%
Beta
0.38
Analyst Price Targets
Based on analyst covering BHC
Wall Street analysts forecast BHC stock price to fall 20.2% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.01
-20.2% Upside
Current Price
C$8.78
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
96.9%
Annualized
90-Day Vol
66.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$10.50
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.32 | C$6.67 – C$13.02 |
| 60 trading days | C$9.89 | C$6.16 – C$15.87 |
| 90 trading days | C$10.50 | C$5.88 – C$18.73 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Bausch Health's stock performance reflects a volatile market environment, with recent news potentially influencing investor sentiment. While the stock has shown significant monthly gains, the year-to-date performance remains negative, prompting a cautious outlook among analysts.
C$8.79
Bausch Health's stock closed at C$8.79, reflecting a 0.46% increase on Monday, yet a 0.45% decline over the past week.
Bull case
Analysts recently upgraded Bausch Health to 'Buy,' and the positive news about Solta Medical's Fraxel FTX® becoming available in Australia could signal potential growth for the company. This development might attract investors looking for opportunities in the health care sector.
Bear case
Despite recent gains, Bausch Health faces challenges with an overall negative profit margin and a bearish outlook from analysts. The stock's performance, along with significant implied moves to analyst targets, indicates potential risks for investors.
Recent Company News
Bausch Health has made headlines recently with several announcements that could impact investor sentiment. Notably, the company announced the availability of Solta Medical's Fraxel FTX® in Australia, which may enhance its product offerings in the dermatology market. Additionally, Bausch's Ortho Dermatologics division recognized the winners of the 2026 Aspire Higher Scholarship, indicating the company's commitment to supporting education in health care. On the financial front, there are discussions about rising earnings estimates, and the stock was upgraded to 'Buy' by analysts, suggesting potential for future growth.
Advertisement
Technical Picture
From a technical standpoint, Bausch Health's stock is trading above both its 50-day moving average of C$7.68 and its 200-day moving average of C$8.09, indicating positive momentum. The stock's 52-week range is C$6.10 to C$11.08, with its current price at approximately 54% of this range. The stock has a beta of 0.38, suggesting lower volatility compared to the broader market. However, trading volume is currently at 853,835 shares, which is lower than the 20-day average volume of 991,405 shares, reflecting decreased trading activity.
Investor Sentiment and Analyst Outlook
Despite the recent upgrades and positive news, analysts maintain a bearish outlook with an average target price of C$7.01, indicating a potential downside of approximately 20.3% from the current price. This cautious sentiment is compounded by Bausch Health's ongoing challenges, including a negative profit margin of -10.1% and a low EPS of -4.07. Investors should weigh these factors carefully when considering their positions in BHC.TO.
Price Action Summary
Bausch Health Companies Inc closed at C$8.79 on Monday, reflecting a 1D increase of 0.46%. Over the past week, the stock has seen a slight decline of 0.45%, yet it remains up significantly by 33.84% over the past month. As investors continue to assess the implications of recent news and market conditions, BHC.TO remains a focal point in the health care sector.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
